Clinical trial · Observational
A Pilot Study to Assess the Follow-up of Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment
A Pilot Study in the Transfer of Follow-up Reviews to the General Practitioner for Prostate Cancer Patients Who Have Undergone Radiotherapy Treatment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Data review showed that the study was underpowered to draw clear conlcusions
Summary
Brief summary (as posted)
This is a pilot study assessing the role of the general practitioner in performing follow-up reviews on men who have recently completed radical radiotherapy for prostate cancer. This will be measured primarily by assessing any changes to the patient's health-related quality of life which will be evaluated by the completion of questionnaires by the participant at each review visit. The study aims to confirm that patient outcome is identical, independent of whether follow-up is performed by a specialist or the patient's General Practitioner.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Reviewed by radiation oncologist
- label
- Reviewed by general practitioner
Primary outcomes (1)
- measure
- To evaluate the patient's health-related quality of life that will be assessed by the patient completing self-administered questionnaires
- timeFrame
- QOL questionnaires will be asked to be completed at baseline, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, 48, 54 and 60 months
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: * Men with a tumour T1-3 stage prostate cancer and have had radical radiotherapy with curative intent * Are between six and twelve months post-treatment completion * Have completed all treatment for prostate cancer (including hormonal deprivation therapy) * Have no evidence of metastatic disease * ECOG performance status of between 0-1 * Remains willing to comply with study requirements * Has maintained contact with an individual general practitioner Exclusion Criteria: * Persistent complications resulting from treatment defined as a minimum Grade 3 treatment toxicity * Unable to complete self-administered questionnaires * Are currently enrolled in a study that requires specialist follow-up * Life expectancy of less than 6 months * Surgery to remove the prostate * Evidence of biochemical failure
References
Publications (0)
Data not yet available